Advanced Search


Study ID Status Title Patient Level Data
FMS10002 Completed A Study of the Tolerance of an Increasing Dose of Oral Fluticasone Propionate in a Formulation for Topical Use in Gastrointestinal Disorders
FMS10004 Completed To Investigate the Effect of Single Oral Doses of Fluticasone Propionate (CCI 18781) on Plasma Cortisol Levels
FMS10005 Completed The safety and tolerance of multiple doses of fluticasone propionate taken from a Diskhaler™
FMS10006 Completed Evaluation of the Safety and Tolerance of Multiple Inhaled Doses of Fluticasone Propionate in Healthy Adult Male Volunteers
FMS10008 Completed To Study the Tolerance of Repeated Doses of Inhaled Fluticasone Propionate and Beclomethasone Dipropionate in Divided Daily Doses of Up to 3mg Per Day
FMS10010 Completed Plasma Level Profiles of Fluticasone Propionate After Single Doses From an Aerosol and Dry Powder Presentation
FMS10011 Completed Report of the bioequivalence study comparing three strengths (100, 250 and 500mcg) fluticasone propionate Rotadisks™
FMS10012 Completed Report of a bioequivalence study comparing three strengths (50, 125 and 250mcg/metered dose) fluticasone propionate by metered-dose inhaler
FMS10013 Completed Pilot Study to Investigate the Buccal Deposition of Inhaled Fluticasone Propionate Administered in Aerosol and Dry Powder Formulations
FMS10014 Completed To Investigate the Pharmacokinetics of a 2mg IV Dose of Fluticasone Propionate (CCI 18781)
FMS10015 Completed To Investigate the Plasma and Urinary Metabolites of Fluticasone Propionate (CCI 18781) Following Intravenous and Oral Dosing
FMS10017 Completed To Investigate the Fate of Single Oral Doses of 16mg Fluticasone Propionate (CCI 18781)
FMS10018 Completed A study to assess the tolerance and effect on the hypothalamo-pituitary-adrenal axis of an increasing dose of oral fluticasone propionate.
FMS10019 Completed To Study Plasma Cortisol Levels After Single 1mg, 2mg and 4mg Night-time Doses of Inhaled Fluticasone Propionate and Beclomethasone Diproprionate
FMS10020 Completed The Systemic Effects of Inhaled Doses of 1mg, 2mg and 4mg Fluticasone Propionate Compared with Those of 1mg and 2mg Beclomethasone Dipropionate: A Pilot Study
FMS10021 Completed A comparison of the plasma level profiles and HPA axis suppressant activities of fluticasone propionate after inhalation of equivalent doses from aerosol and dry powder presentations
FMS10022 Completed A study to assess and compare the safety and plasma levels of repeated inhaled doses of fluticasone propionate (0.5mg, 1mg and 1.5mg daily) in comparison with placebo
FMS10023 Completed A study to investigate the bioequivalence of single 1mg doses of fluticasone propionate given in two different strengths of dry powder inhaler (Rotadisks™) – 250mcg and 500mcg blister
FMS10024 Completed A study to compare the effects of single night-time inhaled doses of fluticasone propionate (0.5, 1.0, 1.5 and 2.0mg) with beclomethasone dipropionate (1, 2, 3 and 4mg) on morning plasma cortisol levels
FMS10026 Completed A randomised, open label, 4-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of single inhaled and intravenous doses of fluticasone propionate and mometasone furoate in healthy subjects Study Listed on
FMS10030 Completed A repeat dose study of inhaled budesonide, FP and MF to assess drug accumulation in adipose tissue Study Listed on
FMS10031 Completed Absolute Bioavailability of FP, BDP, and Budesonide following single inhaled 400mcg dose and assay limits of 50pg/mL. Study Listed on
FMS10032 Completed A study to compare PK of a single doe of fluticasone propionate in healthy male Japanse and Caucasian subjects Study Listed on
FMS10033 Completed A randomised, single-blind, placebo-controlled study with 5-way cross-over design to investigate the systemic pharmacokinetics and pharmacodynamics of single inhaled doses (800mcg and 1600mcg) of Fluticasone Propionate and Mometasone Furoate in healthy subjects. Study Listed on
FMS30002 Completed A multi-centre, randomised, double-blind, parallel group study to validate the changes in tidal breathing lung function parameters versus FEV1 and PD20 assessments due to anti-inflammatory treatment in 5 to 10 years old mild to moderately symptomatic children with asthma.



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.